From the authors

European Respiratory Journal

Volumn 47, Issue 4, 2016, Pages 1288-1290

  Bolhuis, Mathieu S ^a   Tiberi, Simon ^b   Sotgiu, Giovanni ^c   De Lorenzo, Saverio ^d   Kosterink, Jos G ^a,e   Van Der Werf, Tjip S ^a   Migliori, Giovanni Battista ^f   Alffenaar, Jan Willem ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c UNIVERSITY OF SASSARI   (Italy)

^d E Morelli Hospital   (Italy)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; LINEZOLID; MULTIDRUG RESISTANCE PROTEIN; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GRAM POSITIVE INFECTION; HUMAN; LETTER; LOW DRUG DOSE; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; FEMALE; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

FEMALE; HUMANS; LINEZOLID; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84964078867     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02185-2015     Document Type: Letter

References (9)

1. Bolhuis MS, Tiberi S, Sotgiu G, et al. Linezolid tolerability in multidrug-resistant tuberculosis: A retrospective study. Eur Respir J 2015; 46: 1205-1207.
2. Alffenaar JW, van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010; 49: 559-565.
3. World Health Organization (WHO). Tuberculosis fact sheet no. 104. www.who.int/mediacentre/factsheets/fs104/en/Date last updated: October, 2015.
4. Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013; 42: 1614-1621.
5. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007; 27: 476-479.
6. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011; 51: 229-236.
7. Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents 2013; 41: 586-589.
8. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
9. Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012; 67: 2034-2042.